Retatrutide - 20mg
Retatrutide is a next-generation triple-agonist peptide examined in metabolic and energy regulation research models. It is studied for its interaction with GLP-1, GIP, and glucagon-related signaling pathways, making it a central compound in experimental systems exploring glucose regulation, appetite signaling, and energy balance.
Retatrutide peptide is designed to bind three critical metabolic receptors for enhanced therapeutic effect. Activating GLP‑1R improves insulin secretion and satiety, GIPR enhances insulin response and may promote healthy fat metabolism, while GCGRactivation increases energy expenditure. As a next-generation peptide, Retatrutide represents a leap forward in metabolic pharmacotherapy.
Retatrutide is available in both lyophilized vial format for laboratory reconstitution (This format is typically selected for controlled preparation within research environments.) and pre-filled research pen format for immediate experimental handling. (This format allows immediate experimental handling without additional preparation steps.)
Mechanism Overview in Experimental Models
Retatrutide demonstrates activity across three interconnected receptor systems:
• GLP-1 receptor signaling – studied in glucose and satiety pathway research
• GIP receptor signaling – examined in insulin response models
• Glucagon receptor signaling – explored in energy expenditure and metabolic flexibility research
The combined activation profile supports integrated metabolic pathway analysis rather than isolated receptor studies.
Primary research pairing
In experimental research settings, Retatrutide is frequently examined alongside compounds involved in growth hormone–related signaling pathways.
Product Description
-
Synonyms: Retatrutide, LY‑3437943, GLP1‑R
-
Molecular Formula: C₂₂₁H₃₄₂N₄₆O₆₈
-
Molecular Weight: ~4731.33 g/mol
-
CAS Number: 2381089‑83‑2
-
Total Active Ingredient: 20 mg per vial - ( Vial format: lyophilized powder for enhanced stability.)
-
Shelf Life: 36 months (Not re-constituted)